NIH Study Shows No Significant Benefit of Convalescent Plasma for COVID-19 Outpatients With Early Symptoms
August 19, 2021
August 19, 2021
WASHINGTON, Aug. 19 (TNSJou) -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release on Aug. 18, 2021:
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in Februar . . .
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms. The trial was stopped in Februar . . .